ArticleMedicine2026
A FAERS pharmacovigilance analysis of dementia-related adverse event reports.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dementia-related adverse event (AE) reports represent an important area of concern in pharmacovigilance, particularly considering the clinical relevance of cognitive impairment and the complexity of medication use among older adults. This study aims to systematically characterize the reporting patterns of dementia-related AEs and detect disproportionality signals. Dementia-related AE reports in the Food and Drug Administration Adverse Event Reporting System database from the first quarter of 2004 to the first quarter of 2024 were analyzed using the reporting odds ratio and proportional reporting ratio methods. The reports were classified and organized at the Standardized Medical Dictionary for Regulatory Activities Queries and Preferred Term levels to explore the potential association strength between drug-associated dementia and the related drugs and drug categories. We identified a total of 33,772 AE reports related to dementia, with 1103 drugs reported as the main suspected drugs. Overall, immunosuppressants, psycholeptics, and antineoplastic agents were the most frequently reported drug categories. Among them, apixaban exhibited the highest number of AE reports, followed by pimavanserin and lenalidomide. Notably, psycholeptics represented the highest proportion of the top 30 drugs by AE report count. Disproportionality analysis showed that 191 and 135 drugs were associated with potential signals of dementia. This study provides a comprehensive overview of dementia-related AE reports from a pharmacovigilance perspective, offering pharmacovigilance signals that may inform further drug safety evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.